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Abstract.  Cultured bovine capillary endothelial  (BCE) 
cells were found to synthesize and secrete high molec- 
ular mass heparan  sulfate proteoglycans and glycos- 
aminoglycans,  which bound basic fibroblast growth 
factor (bFGF). The secreted heparan  sulfate molecules 
were purified by DEAE cellulose chromatography,  fol- 
lowed by Sepharose 4B chromatography and affinity 
chromatography on immobilized bFGE  Most of the 
heparinase-sensitive  sulfated molecules secreted into 
the medium by BCE cells bound to immobilized bFGF 
at low salt concentrations.  However, elution from 
bFGF with increasing  salt concentrations demonstrated 
varying affinities for bFGF among the secreted hepa- 
ran  sulfate molecules, with part of the heparan  sulfate 
requiring  NaCI concentrations between 1.0 and  1.5 M 
for elution.  Cell extracts prepared from BCE cells also 
contained a bFGF-binding heparan  sulfate proteogly- 
can,  which could be released from the intact cells by a 
short proteinase treatment.  The purified bFGF-binding 
heparan  sulfate competed with  t25I-bFGF for binding to 
low-affinity binding sites but not to high-affinity sites 
on the cells.  Heparan sulfate did not interfere with 
bFGF stimulation of plasminogen activator activity in 
BCE cells in agreement with its lack of effect on bind- 
ing of I:5I-bFGF  to high-affinity sites.  Soluble bFGF 
was readily degraded by plasmin,  whereas bFGF 
bound to heparan  sulfate was protected from proteo- 
lytic degradation.  Treatment of the heparan sulfate 
with heparinase  before addition of plasmin abolished 
the protection and resulted in degradation of bFGF by 
the added proteinase.  The results suggest that heparan 
sulfate released either directly by cells or through pro- 
teolytic degradation of their extracellular milieu may 
act as carrier for bFGF and facilitate the diffusion of 
locally produced growth factor by competing with its 
binding to surrounding  matrix  structures.  Simul- 
taneously, the secreted heparan  sulfate glycosaminogly- 
cans protect the growth factor from proteolytic degra- 
dation by extracellular proteinases,  which are abundant 
at sites of neovascularization or cell invasion. 
variety of sulfated  glycosaminoglycans  are found  in 
mammalian  tissues.  The  major  forms are usually 
covalently linked to a protein core to form large pro- 
teoglycan  macromolecules with several glycosaminoglycan 
chains branching  from a single protein core (12). Proteogly- 
cans are classified either according to their glycosaminogly- 
can composition or according to the properties and antige- 
nicity  of the core protein  (13). Proteoglycans are  widely 
distributed  in  tissues as basement membrane components 
and are found as components of cartilage and connective tis- 
sues,  intercalated  membrane proteoglycans,  and intracellu- 
lar vesicle proteoglycans  (13). Their physiological  function 
is not well-understood,  although  heparan  sulfate  has been 
suggested to play a role in regulation of cell growth (5, 8, 32, 
37) and  in cell attachment  and spreading  (6, 22). 
Fibroblast  growth  factors  are  a  family  of  structurally 
related  polypeptides  characterized  by  a  high  affinity  for 
heparin (9).  The members of this growth  factor family are 
divided into two groups, partly on the basis of their different 
elution patterns from immobilized heparin.  The acidic fibro- 
blast  growth  factors  elute  with  lower  salt  concentrations 
(at  •1  M  NaC1) than  the basic fibroblast growth factors 
(bFGF) ~, which require 1.5 M NaCI or higher  for elution. 
The heparin-binding  growth factors are among the most po- 
tent  known  protein  inducers  of neovascularization  in  ex- 
perimental  models.  They are mitogenic and chemotactic for 
endothelial  cells and are capable of inducing  plasminogen 
activator  (PA) and collagenase production by the cells (27, 
31). Increased proteolytic activity is thought  to be essential 
for the migration of capillary endothelial  cells through limit- 
ing structures  such as basement membranes and intercellular 
matrices (11). Many cell types, including  endothelial  cells, 
possess specific  high-affinity  receptors for bFGF on their 
surface (25,  29,  30),  which mediate the cellular effects of 
1.  Abbreviations  used  in  this paper:  BCE,  bovine capillary endothelial; 
bFGF, basic fibroblast growth factor; PA, plasminogen activator; TX-100, 
Triton X-100. 
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scribed but these appear to have no direct effect on signal 
transduction  (25).  bFGF has been isolated from numerous 
tissues, including placenta, pituitary gland, brain, corpus lu- 
teum, retina, adrenal gland, kidney, bone, and prostate (see 
reference 9), and is synthesized by several cultured normal 
and malignant cell lines (9,  19, 26, 31). bFGF has also been 
reported to be associated with the extracellular  matrix  (2, 
36). 
Among other sites, heparan sulfate proteoglycans are found 
in the micro- and macrovasculature  (3).  Cloned aortic en- 
dothelial cells synthesize heparan sulfate proteoglycans, and 
a small proportion of these molecules have the disaccharide 
structure of heparin  (28) and exhibit anticoagulant activity 
indistinguishable from that of heparin (24). In the present ar- 
ticle, we have characterized an interaction between the en- 
dothelial cell-secreted heparan sulfate and bFGE The bind- 
ing of bFGF has no detectable effect on the interaction  of 
bFGF with its high-affinity receptor but abolishes its interac- 
tion  with  the  low-affinity binding  sites.  Moreover,  bFGF 
bound to heparan sulfate is protected from proteolytic diges- 
tion by plasmin. These interactions may help to explain some 
of the physiologically important features in the action of the 
heparin-binding  growth factors. 
Materials and Methods 
Cell Cultures 
Bovine capillary endothelial cells were isolated from adrenal cortex by pub- 
lished methods (7, 11). The cloned cells were confirmed to be of endothelial 
origin by immunohistochemical staining for factor VIII-related antigen (7). 
The cells were grown in alpha-modified minimal essential medium contain- 
ing 10% calf serum. When the cultures reached confluency, the serum con- 
centration was reduced to 5%. The cells were used between passages 7-11. 
Reagents 
bFGF was purified from term placentas (27, 31). The purified molecule has 
been sequenced and is highly homologous with bFGF purified from the bo- 
vine pituitary (34). Recombinant bFGF was prepared and kindly provided 
by Synergen Inc., Boulder, CO. 
Trypsin, plasmin, soybean trypsin inhibitor, chondroitinase ABC, and 
the purified Flavobacterium heparinum heparinase (EC 4.2.2.7) were ob- 
tained from Sigma Chemical Co. (St. Louis, MO) and were of the highest 
grade available.  The heparinase preparations used were tested for possible 
contaminating proteolytic activity.  They showed no activity when tested at 
concentrations of 50 IU/ml for 3 h in the nsI-fibrin degradation assay. 
Reactigel used for immobilizing bFGF was obtained from Pierce Chemi- 
cal Co. (Rockford, IL), and was used according to manufacturer's proce- 
dure. DE 52  was purchased from Whatman Ltd. (Maidstone, Kent, En- 
gland), and Sepharose 4B was purchased from Pharmacia Fine Chemicals 
(Piscataway,  NJ). Rabbit antiserum against placental bFGF was prepared as 
described (31) and  further affinity purified on a  Reactigel-recombinant 
bFGF column. 
Metabolic Labeling  of  BCE 
Confluent cultures of  BCE cells grown on 100-mm petri dishes were washed 
with serum-free medium and fresh serum-free alpha-modified minimal es- 
sential  medium containing L-[35S]methionine  or  [35S]sodinm sulfate (50 
l~Ci/ml; New England Nuclear, Boston, MA) and 0.1 mM aprotinin (Sigma 
Chemical Co.) was added to the cells. The cultures were incubated for 48 h 
or as indicated, and the conditioned medium was collected, centrifuged at 
2,000 g for 20 rain, and used for isolation of the bFGF-binding molecules. 
Purification of  the bFGF-binding Heparan Sulfates 
Secreted by BCE Cells 
Conditioned medium  from metabolically labeled  BCE  cells containing 
0.5% Triton X-100 (TX-100)  was chromatographed on a column of DE 52 
equilibrated with 0.01 M  PO4,  pH 7.4,  0.15 M  NaCI, and 0.5%  TX-100. 
The column was washed with the equilibration buffer followed by 0.25 M 
NaC1 in the same buffer. The remaining bound material was eluted with 0.5 
M NaCI, resulting in a relatively selective release of the glycosaminogly- 
cans (12). The eluate was adjusted to contain 0.25 M NaC1, and the mole- 
cules were rebound to a small volume of DE 52 (0.5 ml) for concentration. 
The column was washed with 0.01 M Tris-HCl, pH 7.4, containing 0.25 M 
NaCI, and 0.5 % TX-100, and the bound material eluted with a small volume 
of 2.0 M NaC1 in the above buffer.  The eluate was loaded on a Sepharose 
4B column (1  x  50 cm) equilibrated with 0.01 M Tris-HCl buffer, pH 7.4, 
containing 2 M NaCI, and 0.5% TX-100, and the column eluted at a flow 
rate of 4 ml/h.  1-ml fractions were collected, and the radioactivity of the 
fractions was determined. 
As a final step after Sepharose 4B chromatography, the fractions contain- 
ing the radioactively labeled material were pooled, adjusted to contain 0.15 
M NaCI, and applied to a Reactigel column (vol =  1 ml) containing 1 nag 
recombinant bFGE A control column without bFGF was used to monitor 
nonspecific binding of the labeled material. The column was washed with 
5 ml of 0.15 M NaCI in 0.01 M Tris-HCl, pH 7.4, containing 0.5 % CHAPS 
(3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfonate), and  with 
10 ml of the same buffer lacking the detergent. The bound material was 
eluted with a gradient from 0.15 to 2.0 M NaCI in 0.01 M Tris-HCl, pH 
7.4. The radioactivity of the collected fractions was measured, and the salt 
concentration of the fractions was determined by measuring their conduc- 
tance values. The peak fractions were pooled, diluted to 0.25 M NaCI, and 
concentrated by binding the material to 0.5 ml DE 52, from which it was 
eluted with a  small volume of 0.5  M  NaC1 in 0.01 M  PO4,  pH 7.4,  and 
diluted to a final concentration of 0.15 M  NaCl. 
Isolation of  the Cell Layer-associated bFGF-binding 
Heparan Sulfate 
Trypsinization of metabolically labeled cultures was carried out by washing 
the dishes briefly with 0.05%  (wt/vol) trypsin solution containing 1 mM 
EDTA followed by scraping the slightly rounded cells after 2-3 min into 2 
ml of 0.01 M  PO4,  pH 7.4,  containing 0.15  M  NaCI and 0.5%  soybean 
trypsin inhibitor. The cells were removed by centrifugation at 2,000 g for 
10 min. The trypsinate was used for isolation of the bFGF-binding heparan 
sulfate as described for the conditioned medium. 
Immunoprecipitation of  b  FG  F-bound Heparan Sulfate 
For some experiments, heparan sulfate from conditioned medium, cell ex- 
tracts, or matrix preparations was directly bound to bFGF immobilized by 
affinity-purified antibodies on protein A-Sepharose beads (Pharmacia Fine 
Chemicals). The washed beads (25 ~1 containing 5 ~tg bFGF antibodies and 
200 ng bFGF) were incubated with the samples for 20 min on an end-over 
rotator, and the beads were subsequently washed with 0.25 M NaCl in 0.01 
M  PO4 buffer,  pH 7.4,  containing 0.5%  TX-100.  The bound molecules 
were eluted with reducing Laemmli sample buffer and analyzed by elec- 
trophoresis in a  3-16%  continuous gradient polyacrylamide gel (21) fol- 
lowed by autoradiography. 
Plasminogen  Activator  Assay 
BCE cells used for the PA assays were grown in 24-well Falcon dishes. The 
cells were extracted with 0.5 ml of  0.1 M Tris-HCi buffer, pH 8.1, containing 
0.5% TX-100.  The PA activity of the extracts was determined by the nsI- 
fibrin assay as described earlier (11). 25 gl of the cell extract was used in 
the assay, and the PA activity was presented in Ploug units using a urokinase 
preparation as standard (Calbiochem-Behring Corp., La Jolla, CA). 
Receptor  Assays 
Confluent cultures of  BCE cells grown on either 24-well plates or on 60-ram 
dishes were washed and incubated at 4°C for 4 h in serum-free medium con- 
taming  indicated concentrations of the purified promoglycans and  ~2sI- 
bFGF. The binding of ~2Sl-bFGF to high- and low-affinity sites was assayed 
as earlier described for baby hamster kidney (BHK) cells (25). 
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BCE CeU-conditioned Medium and Cell Extract 
Contain a bFGF-binding Molecule 
Conditioned medium from metabolically labeled BCE cells 
was absorbed with bFGF bound to affinity-purified bFGF an- 
tibodies  immobilized on  protein  A-Sepharose.  When  the 
material bound to immobilized bFGF was analyzed by PAGE 
and the gel was exposed for autoradiography, a high molecu- 
lar mass protein heavily labeled with  [35S]methionine  and 
barely entering the gel was detected (arrow in Fig.  1 a). The 
interaction between bFGF and the macromolecule was spe- 
cific,  since  the  molecule  did  not  bind  to  affinity-purified 
bFGF antibodies in the absence of bFGF (Fig.  1 b). Moder- 
ate concentrations of heparin (5 I~g/ml) were sufficient to in- 
hibit this binding (Fig. 1 c). A similar bFGF binding protein 
was associated with the cells. Cell extracts prepared by solu- 
bilizing the cells with a detergent mixture (1% TX-100,  1% 
sodium  deoxycholate,  and  0.5%  SDS  in  0.1  M  Tris-HC1 
buffer, pH 7.4) contained a major high molecular mass pro- 
tein seen at the top of the polyacrylamide gel (Fig.  I d). The 
molecule did not bind to affinity-purified bFGF antibodies 
alone (Fig.  1 e)  and the binding was inhibited by heparin 
(Fig. 1  f). A small amount of background binding to the Pro- 
tein A-Sepharose particles was seen in the control samples 
of Fig.  1, b, c,  e,  and f 
When the cultures were labeled with 35SO+, and the con- 
ditioned medium was assayed for bFGF-binding molecules, 
a high molecular mass-sulfated molecule was detected (data 
not shown). In addition, a diffuse 250-kD band was seen in 
the autoradiograms of polyacrylamide gels of the 35SO4-1a- 
beled material. No related 250-kD [35S]methionine-labeled 
molecules were seen to bind bFGF (Fig.  I  a).  The results 
suggested that the  major binding  molecules were heparan 
sulfates. 
The conditioned medium contained minor amounts of oth- 
er proteins that also bound selectively to bFGF (Fig.  1 a) 
and were not detected after precipitation with purified anti- 
bodies alone (Fig. 1 b). These included proteins with molec- 
ular masses of 47,  68,  230,  and  •280  kD.  These proteins 
were  not  further  characterized.  The  binding  of the  other 
metabolically labeled proteins seen in Fig.  1, b  and e  was 
nonspecific,  since  it occurred when  nonimmune  IgG was 
used instead of the bFGF antibodies (data not shown). 
Isolation of  bFGF-binding Molecules Secreted by BCE 
To  isolate  the  bFGF-binding  molecules,  the  purification 
methods for heparan sulfate glycosaminoglycans were adopt- 
ed  (12).  Secreted  glycosaminoglycans in  the  conditioned 
medium  of 35SO4-1abeled or  [35S]methionine-labeled  BCE 
cultures were bound to DE 52 as described in Materials and 
Methods. The column was washed extensively with 0.25  M 
NaCI in 0.01 M POa buffer, pH 7.3, containing 0.5% TX-100. 
This salt concentration is sufficient to elute most of the se- 
creted glycoproteins and leaves the highly negatively charged 
glycosaminoglycans and proteoglycans bound to the column. 
The column was then eluted with 0.5 M NaC1. After concen- 
Figure  1.  The  binding  of  [35S]methionine-labeled polypeptides 
from BCE cell cultures to immobilized bFGE Confluent cultures 
of BCE  cells  were  labeled  with  [35S]methionine in  serum-free 
medium.  After 24 h, the medium  was collected and the cultures 
washed with PBS and extracted  in a detergent solution.  Both the 
collected medium and the cell extract were absorbed with bFGF im- 
mobilized by afffinity-purified  bFGF antibodies to protein A-Seph- 
arose particles.  The bound material was analyzed on a 9 % poly- 
acrylamide gel with a 3 % stacking gel under reducing conditions. 
A high molecular mass molecule on top of the 9% gel (arrow)  that 
bound to bFGF was observed both in the conditioned medium (a) 
and in the cell extract (d). The molecule did not bind to the immobi- 
lized bFGF antibodies alone (b and e). 5 ~tg/ml heparin prevented 
the binding to immobilized bFGF of  the high molecular mass mole- 
cule from both the medium (c) and the cell extract (f). 
A  35S0, 
J 
411  mekr.__+I  411  ~Idt  R ~5~met 
E)  20  30  40  ^  I0  20  30 
Fra¢lion numb~  Fraction nurn~¢ 
Figure 2. Sepharose 4B chromatography of DE 52 binding material 
from the conditioned medium of 35SO4-1abeled (.4) or [35S]methio- 
nine-labeled (B) BCE cells. Confluent cultures of BCE cells were 
metabolically labeled for 48 h in serum-free medium. The medium 
was applied to a DE 52 column,  and the material eluted between 
0.25-0.5  M NaCI. After concentration,  the eluate was applied to 
a 1 x  50-cm Sepharose 4B column equilibrated with 2.0 M NaC1 
in 0.01 M Tris-HCl buffer, pH 7.4, containing 0.5 % TX-100. The 
column was eluted at a flow rate of  4 ml/h, 1 ml fractions were col- 
lected, and the radioactivity of the fractions was counted. The peak 
fractions were pooled as indicated in the figure. The dashed lines 
indicate the amount of radioactivity bound to antibody-immobilized 
bFGF in 0.15 M NaCI from aliquots of the marked fractions. 
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(Fig.  2).  Two  radiolabeled  peaks  were  detected  in  both 
35SO4-1abeled (Fig. 2 A) and [35S]methionine-labeled (Fig. 2 
B) preparations. A high-salt concentration (2 M NaC1) was 
used during the chromatography to avoid possible ionic in- 
teractions between  the  glycosaminoglycans and  other  se- 
creted molecules. The presence of bFGF-binding molecules 
in the Sepharose 4B fractions was demonstrated by absorb- 
ing aliquots of the fractions on antibody-immobilized bFGF 
after first diluting them to 0.15 M NaC1 (Fig. 2, dashed line). 
For purification of the bFGF-binding molecules, fractions 
from the two peaks observed after Sepharose 4B chromatog- 
raphy of both 35SO4-1abeled and [35S]methionine-labeled  ma- 
terial were pooled and diluted to contain 0.15 M  NaCI and 
were bound to Reactigel-immobilized bFGE Approximately 
50% of the 35SO4-1abeled  molecules from the first peak and 
'~25 % of the labeled molecules from the second peak re- 
mained bound to the column after extensive washing.  The 
nonbinding fraction probably represented molecules other 
than those that were heparan sulfate related (see below). The 
material bound to bFGF was eluted with a 0.15-2.0 M NaCI 
gradient (Fig. 3 A). The majority of the radiolabeled mole- 
cules from the two 35SO4-1abeled Sepharose 4B peaks eluted 
with 0.75 M  NaC1,  although some of the molecules in the 
second Sepharose 4B peak required higher NaC1 concentra- 
tions for elution. When material from the second Sepharose 
4B peak bound to immobilized bFGF was eluted with se- 
quential extensive washes with increasing NaC1 concentra- 
tions, 22% of the total counts recovered eluted with 0.5 M, 
63% with 1.0M, 13% with 1.5 M, and2% with 2.0 M NaC1. 
When the 35SO4-1abeled material that eluted with concentra- 
tions >1.0 M  NaC1 was rebound to bFGF at 0.5 M  NaC1, 
washed with  1.0 M  NaC1,  and re-eluted with 2.0 M  NaCI, 
>60%  of the  material  was  recovered in  the  2  M  eluate, 
confirming that this fraction includes molecules that have a 
high affinity for bFGE  The [35S]methionine-labeled mate- 
rial from the first Sepharose 4B peak eluted from immobi- 
lized bFGF with the same salt concentration as the corre- 
sponding  35SO4-1abeled molecules  (Fig.  3  B).  All  of the 
[35S]methionine-labeled material  from the  second  Sepha- 
rose 4B peak eluted from the immobilized bFGF at low-salt 
concentrations. Most likely the second peak represented pro- 
teins that initially bound to DE 52 via the proteoglycans but 
had dissociated during the Sepbarose 4B chromatography at 
2 M NaC1, or proteins that bound directly to DE 52 with rel- 
atively high affinity. 
Characterization of  the bFGF-binding Molecules 
Binding of the 35SOa-labeled molecules to immobilized bFGF 
was abolished by pretreatment with purified Flavobacterium 
Figure 4. Effect of heparinase and chon- 
droitinase ABC treatment on the bind- 
ing of 35SO4-1abeled molecules to bFGF. 
Concentrated metabolically  labeled sam- 
pies from DE 52 were incubated for 6 h 
at 37°C with heparinase (a), chondroi- 
tinase  ABC  (b),  or without  additions 
(c). The treated material was bound to 
immobilized bFGF and analyzed  by SDS- 
PAGE. The bound molecules were vi- 
sualized by autoradiography. 
heparinase (5 IU/ml; incubated for 6 h at 37°C) but not by 
chondroitinase ABC (5 IU/ml; incubated for 6  h  at 37°C; 
Fig. 4). After separation of the DE 52 eluted material in the 
Sepharose 4B column, the first peak from the column con- 
mined  a  SO4-1abeled  high  molecular mass  bFGF-binding 
molecule as visualized after SDS-PAGE and autoradiogra- 
phy (Fig. 5 a). A similar molecule was seen in preparations 
of the  conditioned medium  from  [35S]methionine-labeled 
BCE cell cultures (Fig. 5 c). These molecules appeared to 
be identical to the molecule initially observed to bind to 
bFGF (Fig.  1 a). When the 35SO4-1abeled and the [35S]me- 
thionine-labeled high molecular mass molecules were pre- 
treated with 0.05 % (wt/vol) trypsin and the enzyme was in- 
hibited after 6 h incubation at 37°C by adding 0.5% soybean 
trypsin inhibitor,  a  conversion of the 35SO4-1abeled mole- 
cule to a smaller form still binding to bFGF was seen (Fig. 
5 e). No [35S]methionine-labeled molecules bound to bFGF 
after trypsin treatment (data not shown). 
A smaller 35SO4-labeled  heparinase-sensitive  molecule from 
the second peak of the Sepharose 4B column bound to im- 
mobilized bFGF  (Fig.  5  b).  Neither the size nor binding 
of this molecule was affected by trypsin (Fig.  5 f).  After 
[35S]methionine  labeling, no corresponding molecules were 
found bound to immobilized bFGF (Fig.  5 d).  The results 
suggest that the high molecular mass bFGF-binding mole- 
cule is  a  heparan sulfate glycosaminoglycan, which has  a 
protein core sensitive to degradation by trypsin. A core pro- 
tein for the smaller secreted heparan sulfate species could not 
be identified by metabolic labeling with methionine (or cys- 
teine) or by sensitivity to trypsin treatment. 
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Figure 3. Gradient elution of~sSO4-1abeled 
(A) or  [35S]methionine-labeled  (B) mole- 
cules  from  immobilized  bFGE  Labeled 
material from the Sepharose 4B peaks I and 
II (Fig. 2) was applied to a Reactigel-bFGF 
column. The bound molecules were eluted 
with a continuous 0.15-2.00 M NaCI gra- 
dient in 0.01 M Tris-HCl, pH 7.4. (4) *, 4B 
peak I; o, 4B peak II. (B) A, 4B peak I; zx, 
4B peak II. 
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Metabolically  labeled molecules  which eluted  from immobilized 
bFGF between 0.5 and 2.0 M NaCI were analyzed in a reducing 
3-16%  continuous  polyacrylamide  gel followed by autoradiogra- 
phy. The bFGF-binding molecules from the Sepharose 4B peak I 
consisted of high molecular mass material labeled both with 35SO4 
(a)  and  with  [35S]methionine (c).  The bFGF-binding  molecules 
from peak II consisted of molecules labeled with 35SO4 (b), but no 
[35S]methionine-labeled material  from peak II remained bound to 
the bFGF column after washing with 0.5 M NaCI (d). Lanes e and 
fare the same as lanes a and b except that the samples were treated 
with 0.05 % trypsin  for 6 h before binding to immobilized bFGE 
Treatment  of 35SO4-1abeled BCE cells  with  0.05 % trypsin for 5 
min results in release of high molecular mass material, which binds 
to immobilized bFGF (g). Treatment with heparinase (5 IU/ml for 
6 h) abolishes the binding (h). 
In addition  to these major bFGF-binding molecules,  the 
absorption of the first peak from the Sepharose 4B column 
to  immobilized bFGF  resulted  in  binding  of [35S]methio- 
nine-labeled 230- and 280-kD proteins (Fig.  5 c).  The two 
molecules  appeared  similar  to  those  observed  to  bind  to 
bFGF in the unfractionated conditioned medium (Fig.  1 a). 
Extracellular bFGF-binding Heparan Sulfate 
in BCE Cells 
The cell-associated heparan sulfate proteoglycans were stud- 
ied after solubilizing the molecules by proteolytic digestion. 
Trypsin degrades the protein core mediating the binding of 
heparan sulfate proteoglycans to the cell membrane (14).  A 
short trypsinization of metabolically labeled BCE cells re- 
suited in the release from the cell layer of 35SO4-1abeled ma- 
terial.  After isolation of the DE 52 binding fraction of the 
trypsin-solubilized material,  it was bound to antibody-im- 
mobilized bFGF (Fig. 5 g). The trypsin releasate contained 
a  major heparan  sulfate  species that migrated in  SDS  gel 
electrophoresis slightly faster than the larger molecule ob- 
tained  from the  conditioned medium.  The ability of these 
molecules  to  bind  to  bFGF  was  abolished  by  heparinase 
treatment (Fig.  5 h). 
Quantitation of the bFGF-binding Heparan Sulfate 
Secreted by BCE Cells 
To quantitate the amount of bFGF-binding heparan sulfate 
secreted by the BCE cells, the amount of immobilized bFGF 
required  to bind all the 35SO4-1abeled heparan sulfate in a 
sample of BCE cell-conditioned medium was determined. 
Excess amounts of antibody and Protein A-Sepharose were 
used to insure that the limiting factor in the absorbent was 
bFGE After a 24-h incubation in serum-free medium, a 60- 
mm dish  containing  0.6  mg  cellular  protein  had  secreted 
enough heparan sulfate to bind ,,o500 ng of added bFGF (data 
not shown). 
To quantitate  the  proportion of the  heparan  sulfate that 
is capable of binding to immobilized bFGF from the total 
amount of heparan sulfate secreted by the cells, the following 
experiments were performed (Fig.  6).  First,  the  material 
from each  of the  two peaks obtained  after  Sepharose 4B 
chromatography was digested with heparinase. Both digested 
and control samples were repurified using DE 52 (Fig. 6 A, 
columns 1 ).  This treatment was sufficient to degrade 52 % 
of the sulfated molecules present in peak I and 20% of the 
molecules in peak II. In the second experiment, when the 
35SO4-1abeled molecules  from peak I  were applied to  the 
bFGF column (Fig. 6 A, columns 2), 50% of the radioactiv- 
ity bound to bFGF, while only 22 % of the radioactivity in 
peak II bound to the column.  When the material was pre- 
treated  with  heparinase,  >90%  of the  binding  from each 
peak was lost. Similar results were obtained when the [35S]- 
A 
4B  peokT 
3~304  B  ~'5~met 
4B peokX  4B pNk T  4BNOk 1T 
16  24 
12  18 
x 
Figure 6. Effect of heparinase treatment on the binding of the BCE 
cell-secreted 35SO4-1abeled (A) or [35Slmethionlne-labeled (B) mol- 
ecules to DE 52 (columns 1 ) or immobilized bFGF (columns 2). 
Pooled fractions from the two peaks of the Sephamse 4B column 
were diluted to 0.15 M NaC1 and incubated either with DE 52 or 
with bFGF immobilized to protein A-Sepharose  by affinity-puri- 
fied antibodies (open columns). This binding was compared to the 
binding of heparinase-treated samples (shaded columns) to the ab- 
sorbents.  The difference between open and shaded columns  indi- 
cates the amount of  heparinase-sensitive metabolically labeled mol- 
ecules in the samples. The decrease  in the 35SO4-1abeled material 
binding to DE 52 (,4, columns 1 ) equals the decrease in the material 
binding to immobilized bFGF (A, columns 2). This suggests that 
almost all of the BCE cell-secreted  heparan sulfate molecules bind 
to immobilized bFGF at 0.15 M NaCI.  A slight difference in the 
binding of heparinase-sensitive  [35S]methionine-labeled molecules 
from Sepharose 4B peak I to DEAE-collulose (B, columns 1 ) com- 
pared to their binding to bFGF (B, columns 2) was observed. Only 
a  small  proportion  of the  [35S]methionine-labeled molecules  in 
peak  II bound  to  antibody-immobilized  bFGE  Open columns, 
before  heparinase  digestion;  shaded columns, after  heparinase 
digestion. 
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fmol bFGF bound to 
low affinity  sites  high affinity  sites 
125I-bFGF  (2.5  ng in  1 ml) 
~25I-bFGF  +  heparan sulfate (10,800  cpm) 
~25I-bFGF  +  heparinase (2.0  U) 
~'5I-bFGF +  heparinase (boiled 5 min) 
t2~I-bFGF +  heparan sulfate (boiled 5 min) 
t25I-bFGF +  heparan sulfate (heparinase 
treated, boiled 5 min) 
28.0  +  1.0  3.1  +  0.3 
10.4  +  1.5  2.6  +  0.3 
10.0  +  2.0  ND 
27.2  +  1.0  ND 
12.2  +  1.5  ND 
20.4  +  2.0  ND 
~zSI-bFGF was bound to cultures of confluent BCE cells (4 x  105) grown on 60-mm dishes (reference 25). The purified  heparan sulfate preparation tested for in- 
hibitory effect on bFGF binding was preincubated with t2~I-bFGF for 15 min. The samples were added to the cells and incubated at 4°C for 2 h. The unbound 
label was removed and ~esI-bFGF bound to low affinity sites was released by 2 M NaCI at neutral pH and quantitated.  ~2SI-bFGF bound to the high affinity sites 
was solubilized with detergent and quantitated. 
methionine-labeled proteoglycans from Sepharose 4B peak 
I were treated with heparinase (Fig. 6 B). Thus, it appears 
that  essentially  all  of the  heparinase-sensitive  molecules 
present in the two Sepharose 4B peaks are capable of  binding 
to bFGF at low-salt concentrations. 
Biological Activity of  b  FG  F-binding Heparan Sulfates 
To assess the potential biological role of the bFGF-binding 
heparan sulfate, several experiments were performed. First, 
the ability of heparan sulfate to compete with the binding of 
125I-bFGF to low- and high-affinity sites on BCE cells was 
measured.  Increasing  amounts of a  crude heparan  sulfate 
preparation effectively decreased the amount of ~25I-bFGF 
bound to the cells. The preparation inhibited only the low- 
affinity binding of ~25I-bFGF to the cells and had no effect 
on binding of the label to high-affinity sites (Table I). 
The low-affinity binding of ~25I-bFGF could be reduced 
up to 70% by the addition of purified heparan sulfate glyco- 
saminoglycans eluted from the immobilized bFGF column. 
To demonstrate that the inhibition was indeed mediated by 
heparan sulfate molecules, the purified heparan sulfate was 
treated with heparinase and tested for inhibition of ~25I-bFGF 
binding.  The heparinase  by  itself reduced the  binding  of 
~25I-bFGF to  low-affinity sites  presumably  because  it  de- 
graded the cell-associated heparan sulfate molecules which 
constitute the low-affinity binding sites (25). The heparinase 
activity could be inhibited by boiling, which only slightly 
affected the inhibitory activity of the heparan sulfate. After 
heparinase digestion of purified heparan sulfate followed by 
boiling to inactivate the enzyme, only 20 % of the inhibitory 
activity remained.  The nature of this remaining activity is 
unknown. It does not appear to be due to undigested heparan 
sulfate molecules, since the inhibitory activity did not bind 
to DE 52 (data not shown). 
To support the finding that heparan proteoglycans do not 
prevent the binding of bFGF to the high-affinity receptors 
that mediate the stimulation of the cells by bFGF (25,  29, 
30),  we tested the effect of the purified heparan sulfate on 
the stimulation of cellular PA activity by bFGE Increasing 
amounts of bFGF were mixed with a constant amount of the 
purified heparan sulfate preparation from the Sepharose 4B 
peak II, and the mixture was incubated with BCE cells for 
16 h. The amount of heparan sulfate used was equal to the 
concentration needed to cause a 50%  reduction in the low- 
affÉnity binding of 2.5 ng of ~25I-bFGF to the cells. As shown 
in  Fig.  7,  the heparan  sulfate preparation alone caused  a 
slight but consistent decrease in the level of the cell-associ- 
ated PA activity. The reason for this decrease is unknown. 
However, the addition of heparan sulfate did not affect the in- 
crease of PA activity caused by increasing amounts of bFGE 
This result is consistent with the inability of the heparan sul- 
fate to block bFGF binding to its high-affinity receptor. 
Other studies have described a protective effect of heparin 
on the inactivation ofbFGF by pH or temperature (10). Since 
active proteolysis may occur both at regions of angiogenesis 
and wound repair, we investigated whether heparan sulfate 
protected bFGF from proteolytic degradation. Purified and 
iodinated bFGF was diluted in 0.01 M  PO4,  pH 7.4,  con- 
mining 20 mM Hepes and 0.05 % gelatin. The labeled growth 
factor was degraded during a 6-h incubation at 37°C by 5 Ixg/ 
ml of plasmin (Fig.  8, a  and b).  This degradation is effec- 
tively prevented by adding either heparin (250 ng/ng bFGF; 
Fig. 7 c) or purified BCE cell-secreted heparan sulfate (Fig. 
8 e) to the  I/5I-bFGF preparation.  The protective effect is 
greatly decreased by a 6-h pretreatment of the heparin or the 
heparan  sulfate preparations  with  heparinase  (5  IU/ml  at 
~50C 
"~  0.~ S 
I  1  I  I  I  I 
0  03  1.0  :50  I0.0  3DO 
bFGF  (ng/ml) 
Figure 7. Effect of purified BCE cell-secreted heparan sulfates on 
the biological activity of bFGE Increasing concentrations of bFGF 
were added to cultures of BCE cells either in the absence (o) or 
in the presence (e) of a constant amount of BCE cell-secreted 
purified heparan sulfate. The concentration of heparan sulfate used 
was sufficient to cause >50% inhibition of the low-affinity  binding 
of ~25I-bFGF to BCE cells.  After the incubation, the cells were 
washed, extracted in 0.5% TX-100, and the plasminogen activator 
activity of the lysate was determined by the ~25I-fibrin  degradation 
assay. 
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BCE cell-secreted  heparan sulfates and heparin.  ~25I-bFGF (1 ng/ 
ml; a) was rapidly degraded when incubated for 6 h with 5 ~tg/ml 
plasmin (b). Addition of heparan sulfate (c) or heparin (e) resulted 
in protection of the growth factor from proteolysis. Pretreatment of 
the glycosaminoglycans with heparinase before addition of plasmin 
resulted in loss of the protective effect (c and f). 
37°C; Fig. 8, d and f). Neither the heparin nor the purified 
heparan sulfate had any effect  on the plasmin activity as mea- 
sured by the 125I-fibrin degradation assay (data not shown). 
The  effect of plasmin  treatment  on bFGF  activity  was 
tested in the following way.  bFGF was  incubated with or 
without plasmin, aprotinin was added to both samples to in- 
hibit the enzyme, and the bFGF preparations were tested for 
their biological activity (Table I.I). A significant stimulation 
of cell-associated PA activity in cultures of BCE cells was 
seen only by the control bFGF preparation, whereas no stim- 
ulation by the plasmin-treated bFGF was observed, indicat- 
ing that the bFGF had been degraded. In contrast, when the 
plasmin treatment was carried out in the presence of heparin 
or purified BCE secreted heparan sulfate, the bFGF prepara- 
tion retained its activity. In fact, both the heparan sulfate and 
heparin increased the stimulatory activity of bFGF recov- 
ered after the incubation. The difference in the recovered ac- 
tivities did not appear to be due to stimulation caused by 
heparan sulfate or heparin. Rather, it was due to partial loss 
of activity in the control bFGF preparation during the in- 
cubation.  This can be seen by comparing the  stimulation 
caused by bFGF after the incubation to the stimulation shown 
in Fig. 7. In addition, Fig. 7 indicates that when heparan sul- 
fate and bFGF are added to the cells without prior incuba- 
tion, there is no effect of heparan sulfate on the stimulation 
by bFGE The results are consistent with the above data and 
confirm that bFGF bound to heparan sulfate is not degraded 
under these conditions and that the complex retains its bio- 
logical activity. 
Discussion 
The strong binding to heparin is a characteristic feature of 
the fibroblast growth factors. Complex formation protects both 
acidic fibroblast growth factors and bFGFs from heat and 
acid inactivation (10).  However, the biological significance 
of the interaction is not clear as heparin is rarely present in 
vivo. Endothelial cells do synthesize and release heparan sul- 
fate, which has the disaccharide structure and anticoagulant 
activity of heparin (24, 28).  The interaction with heparan 
sulfate  or  heparan  sulfate proteoglycans rather  than  with 
heparin is more likely to be relevant in the action of bFGE 
In this study we have characterized some of the properties 
of the bFGF-binding heparan sulfate molecules produced by 
BCE cells. 
The bFGF-binding heparan sulfate secreted by BCE cells 
consists of two different classes  of molecules.  The larger 
molecule contains a protein core, whereas the existence of 
a core protein for the smaller heparan sulfate is not certain 
since it is not labeled by methionine (or cysteine) and is resis- 
tant  to  trypsin  degradation.  The  smaller  heparan  sulfate 
elutes from columns of immobilized growth factor at slightly 
Table II. Protection of  the Biological Activity of  bFGF  from Plasmin Degradation by Purified Heparan Sulfate 
and Heparin 
Plasminogen activator activity 
in cell extracts 
no  additions 
bFGF  (5  ng/ml) 
bFGF  +  plasmin (5  p.g/ml) 
bFGF +  plasmin +  heparan sulfate (10,800 cpm/ml) 
bFGF +  plasmin +  heparin (1 lxg/ml) 
bFGF (15 ng/ml) 
bFGF +  plasmin (5 Ixg/ml) 
bFGF +  plasmin +  heparan sulfate (10,800 cproJml) 











Basic FGF was diluted in a 0.01  M  PO4 buffer, pH 7.4, containing 0.04%  gelatin, and incubated alone with purified heparan sulfate or with heparin for 1 h at 
20°C. Plasmin was added as indicated and the incubation was continued for 3 h at 37°C, after which the enzyme was inhibited by aprotinin (10 p,g/ml) and 1-ml 
aliquots of the samples were added to BCE cells grown on 24-well plates. The plasminogen activator activity of the cell cultures was measured after 16 h incubation. 
The  values shown represent mean activities from four parallel measurements. 
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This may reflect a structural difference between the bFGF- 
binding portions of  the molecules, such as a difference in the 
degree of sulfation, or may simply be due to steric interfer- 
ence in the case of the larger proteoglycan. 
An interesting feature of the isolated bFGF-binding hepa- 
ran sulfate proteoglycan fraction was the copurification of 
some unidentified protein components. These proteins did 
not copurify with the smaller heparan sulfate species. It also 
appears that these proteins did not bind directly to bFGF, 
since their binding to immobilized bFGF was sensitive to 
heparinase treatment.  Heparan sulfate proteoglycans have 
affinity towards several secreted and matrix molecules, such 
as collagens (35), fibronectin (17, 35), laminin (4,  17), and 
vitronectin (1). The binding of heparan sulfate proteoglycans 
to fibronectin may also involve the protein core of the pro- 
teoglycan (17). The proteins observed to copurify with the 
heparan sulfate proteoglycan, therefore, may represent com- 
ponents of high molecular mass aggregates of structural pro- 
teins secreted by the cells (33).  The identification of these 
proteins is currently in progress. 
Heparan sulfate glycosaminoglycans are a common con- 
stituent of extracellular matrices (14). In cultures of endothe- 
lial cells, they account for the majority of extracellular sul- 
fated glycosaminoglycans (20).  These extracellular heparan 
chains are thought to be a major bFGF-binding component 
in cultured BHK cells (25),  since the binding can be com- 
peted with heparin and the sites are sensitive to heparinase 
treatment. The present finding that the endothelial cell-se- 
creted heparan sulfate competes with binding of bFGF to the 
low-affinity sites is in agreement with previous results sug- 
gesting that extracellular matrix heparan sulfate can bind the 
growth factor (2, 25).  Indeed, such a heparan sulfate pro- 
teoglycan was released from the cell surface by mild trypsini- 
zation of the cells. 
Extracellularly located proteoglycans are either membrane- 
bound through their hydrophilic protein core or are bound 
to other membrane-attached molecules of the matrix (cf. 
references 13,  14). The release of these pericellular glyco- 
saminoglycans may occur through limited proteolysis of the 
membrane-embedded protein core, as suggested for the inte- 
gral membrane heparan sulfate in cultured colon carcinoma 
cells (15, 16) or in cultured rat hepatocytes (18). In the pres- 
ent study, we demonstrated the release of a bFGF-binding 
heparan sulfate from the extracellular structures of endothe- 
lial cells by trypsin. The relationship between cell surface 
heparan sulfate and the secreted heparan sulfate in BCE cell 
cultures was not studied, but preliminary pulse labeling ex- 
periments demonstrated that the bFGF-binding molecules 
appear in the conditioned medium and on the cell surface 
with the same rate. This suggests that the molecules may not 
be directly related; i.e., that the soluble heparan sulfate is not 
exclusively derived from the cell-associated form, or that the 
cell-associated molecules are not primarily taken up from 
the conditioned medium (unpublished observations). 
Binding to heparin considerably increased the resistance 
of bFGF to degradation by plasmin. The less sulfated hepa- 
ran proteoglycans can also effectively protect bFGF from 
proteolytic degradation. In spite of the effective protection, 
heparan sulfate does not inhibit the biological activity of 
bFGF. This was shown by the ability of the heparan sulfate- 
bound bFGF to interact with the high-affinity sites on BCE 
cells and by the stimulation of PA activity by bFGF in the 
presence of heparan sulfate proteoglycans. It is an intriguing 
possibility that pericelhlar hydrolytic activities may release 
bFGF located in extracellular complexes (2, 36). Two possi- 
bilities seem to exist for this process.  In one, cell-derived 
heparanases would degrade the heparan sulfate releasing free 
bFGF,  while in the other, proteinases would degrade the 
protein core of the heparan sulfate proteoglycans releasing 
bFGF-heparan  sulfate glycosaminoglycan complexes.  We 
favor the  latter possibility,  since  heparinase treatment of 
bFGF-heparan sulfate complexes resulted in subsequent en- 
hanced inactivation of the growth factor by proteinases.  Thus, 
bFGF released by heparinase from the matrix (2) may be rel- 
atively short lived in vivo if proteolytic activity is present. 
At sites of tumor growth,  neovascularization, and wound 
healing, high levels of  proteolytic enzymes are produced that 
would limit the availability  of bFGE Conversely, the release 
of bFGF from heparan sulfate proteoglycancomplexes by 
proteolytic degradation of the protein core would result in 
the  formation of bFGF-glycosaminoglycan complexes.  In 
this form the glycosaminoglycans  might serve as carriers for 
the growth factor by protecting it from inactivation by pro- 
teinases. In addition, complex formation may facilitate bFGF 
diffusion. Since free bFGF would probably have an extreme- 
ly limited diffusion capability because of its effective binding 
to the abundant matrix proteoglycans, this may be another 
important aspect of the in vivo function of bFGF-heparan 
sulfate complexes. 
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